ReviewInternational journal of molecular sciences2020
A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Delayed Therapeutic Response to Oral Corticosteroids and Rituximab Leading to Dialysis Independence in a Patient with Treatment-resistant C3 Glomerulonephritis.Internal medicine (Tokyo, Japan) · 2026Article
- Diagnosis and treatment in adult patients with C3 glomerulopathy in Japan: a real-world survey.Clinical and experimental nephrology · 2026Article
- New Anticomplement Drugs in Nephrology: Mechanism and Indication.Kidney & blood pressure research · 2026Review
- Immune complex handling in transplantation: central roles for complement factor H, animal models, and translational implications.Frontiers in immunology · 2026Review
- A very rare cause of oliguric acute kidney disease: crescentic C3 glomerulopathy.Oxford medical case reports · 2025Article
- Article
- Kidney Damage in a Post-Hematopoietic Stem Cell Transplantation Patient With Dense Deposit Disease and Thrombotic Microangiopathy-Like Changes.Kidney international reports · 2025Article
- Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy.Kidney international reports · 2025Article
- Pegcetacoplan for the Treatment of Paediatric C3 Glomerulonephritis: A Case Report.Nephrology (Carlton, Vic.) · 2025Article
- Case report: a rare concurrence of dense deposit disease in an adolescent patient with IgA nephropathy.BMC pediatrics · 2025Article
- Establishing the Future Direction of Clinical Outcomes in C3 Glomerulopathy: Perspectives From a Patient and a Physician.Kidney medicine · 2025Review
- Iptacopan treatment for recurrent dense deposit disease after kidney transplant: A case report.SAGE open medical case reports · 2025Article
- Expert Discussion on Challenges in C3G Diagnosis: A Podcast Article on Best Practices in Kidney Biopsies.Advances in therapy · 2023Article
- Diagnostic Problems in C3 Glomerulopathy.Biomedicines · 2023Article
- Daratumumab in the treatment of C3 glomerulopathy with monoclonal gammopathy: a case report and literature review.Frontiers in medicine · 2023Article
- Complement C3 Regulates Inflammatory Response and Monocyte/Macrophage Phagocytosis ofInternational journal of molecular sciences · 2022Article
- The role of the complement system in primary membranous nephropathy: A narrative review in the era of new therapeutic targets.Frontiers in immunology · 2022Review
- Generation and Characterization of Mouse Models of C3 Glomerulonephritis With CFI D288G and P467S Mutations.Frontiers in physiology · 2021Article
- Treatment of C3 Glomerulopathy in Adult Kidney Transplant Recipients: A Systematic Review.Medical sciences (Basel, Switzerland) · 2020Article
- Genetic and pathological findings in a boy with psoriasis and C3 glomerulonephritis: A case report and literature review.Molecular genetics & genomic medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In April 2012, a group of nephrologists organized a consensus conference in Cambridge (UK) on type II membranoproliferative glomerulonephritis and decided to use a new terminology, "C3 glomerulopathy" (C3 GP). Further knowledge on the complement system and on kidney biopsy contributed toward distinguishing this disease into three subgroups: dense deposit disease (DDD), C3 glomerulonephritis (C3 GN), and the CFHR5 nephropathy. The persistent presence of microhematuria with or without light or heavy proteinuria after an infection episode suggests the potential onset of C3 GP. These nephritides are characterized by abnormal activation of the complement alternative pathway, abnormal deposition of C3 in the glomeruli, and progression of renal damage to end-stage kidney disease. The diagnosis is based on studying the complement system, relative genetics, and kidney biopsies. The treatment gap derives from the absence of a robust understanding of their natural outcome. Therefore, a specific treatment for the different types of C3 GP has not been established. Recommendations have been obtained from case series and observational studies because no randomized clinical trials have been conducted. Current treatment is based on corticosteroids and antiproliferative drugs (cyclophosphamide, mycophenolate mofetil), monoclonal antibodies (rituximab) or complement inhibitors (eculizumab). In some cases, it is suggested to include sessions of plasma exchange.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.